Compare ETON & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | CGEM |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2018 | 2020 |
| Metric | ETON | CGEM |
|---|---|---|
| Price | $56.20 | $21.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $39.33 | $30.13 |
| AVG Volume (30 Days) | 428.6K | ★ 719.6K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $79,950,000.00 | N/A |
| Revenue This Year | $40.90 | N/A |
| Revenue Next Year | $47.23 | $5.20 |
| P/E Ratio | $136.12 | ★ N/A |
| Revenue Growth | ★ 104.94 | N/A |
| 52 Week Low | $14.27 | $5.68 |
| 52 Week High | $66.37 | $23.19 |
| Indicator | ETON | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 49.17 | 46.94 |
| Support Level | $15.75 | $11.87 |
| Resistance Level | $66.37 | $23.19 |
| Average True Range (ATR) | 2.54 | 0.98 |
| MACD | -1.32 | -0.35 |
| Stochastic Oscillator | 18.40 | 42.27 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.